<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895205</url>
  </required_header>
  <id_info>
    <org_study_id>PP-02</org_study_id>
    <nct_id>NCT01895205</nct_id>
  </id_info>
  <brief_title>Treatment of Women After Severe Postpartum Haemorrhage</brief_title>
  <acronym>PP-02</acronym>
  <official_title>A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioStata</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to get explorative information about IV high single dose
      infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of severe
      PP-IDA evaluated as physical fatigue
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Fatigue</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb concentration</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-ferritin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue symptoms</measure>
    <time_frame>from baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum depression</measure>
    <time_frame>From week 1 to 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADRs)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-iron</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-transferrin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transferrin saturation (TSAT)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reticulocyte count</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change mean reticulocyte haemoglobin content (CHr)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in anaemia symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in gastrointestinal symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Severe Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogenic RBC transfusion is dosed to trigger Hb:
Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC
Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron isomaltoside 1000</intervention_name>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <other_name>Monofer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red blood cell transfusion</intervention_name>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PPH &gt; 1000 mL

          2. Hb ≥ 5.5 and ≤ 8.0 g/dL (≥ 3.5 and ≤ 5.0 mmol/L)

          3. Willingness to participate and signed the informed consent form

        Exclusion Criteria:

          1. Women aged &lt; 18 years

          2. Multiple births

          3. Peripartum RBC transfusion

          4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and
             haemosiderosis)

          5. Known hypersensitivity to parenteral iron or any excipients in the investigational
             drug products

          6. Women with a history of active asthma within the last 5 years or a history of multiple
             allergies

          7. Known decompensated liver cirrhosis and active hepatitis

          8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome
             (defined according to &quot;Dansk Selskab for Obstetrik og Gynækologi guidelines&quot;)

          9. Active acute infection assessed by clinical judgement

         10. Rheumatoid arthritis with symptoms or signs of active joint inflammation

         11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia
             (known haematologic disorder other than iron deficiency)

         12. Not able to read, speak and understand the Danish language

         13. Participation in any other clinical study where the study drug has not passed 5
             half-lives prior to the baseline

         14. Any other medical condition that, in the opinion of Investigator, may cause the
             patient to be unsuitable for completion of the study or place the patient at potential
             risk from being in the study. For example, a malignancy, uncontrolled hypertension,
             unstable ischaemic heart disease or uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

